Levitra

Vardenafil, the active ingredient in Levitra, is a Phosphodiesterase type 5 inhibitor presented as a 5 mg, 10 mg, 20 mg tablet for oral use. It treats erectile dysfunction in adult males by improving the ability to achieve and maintain an erection. GNH USA supplies Levitra as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Levitra belongs to the phosphodiesterase type 5 inhibitor class and is used to manage erectile dysfunction. - Erectile dysfunction (organic): improves the ability to achieve an erection sufficient for sexual activity. - Erectile dysfunction (psychogenic): facilitates erection when the cause is psychological stress or anxiety. - Erectile dysfunction after prostate surgery: supports erectile function in men recovering from radical prostatectomy.

Common Side Effects: - Headache: mild to moderate pain often described as tension‑type. - Flushing: warmth and redness, typically on the face or neck. - Nasal congestion: sensation of a blocked or runny nose. - Dyspepsia: mild stomach discomfort or indigestion.

Serious or Rare Side Effects: - Priapism: prolonged erection lasting more than four hours requiring medical attention. - Sudden vision loss: abrupt loss of vision in one or both eyes, possibly indicating non‑arteritic anterior ischemic optic neuropathy. - Sudden hearing loss: rapid loss of hearing, sometimes accompanied by tinnitus or vertigo.

Before initiating therapy, patients should be evaluated for cardiovascular health and potential contraindications. - Medical evaluation: assess cardiovascular status and suitability for sexual activity. - Nitrate therapy: avoid concurrent use due to risk of severe hypotension. - Alpha‑blocker use: monitor blood pressure closely if combined. - Retinal disorders: use with caution in patients with pre‑existing eye conditions. - Store at ambient temperature: keep below 25 °C, retain in original packaging, and protect from moisture.

Vardenafil may interact with several drug classes, requiring careful management. Major Interactions (Avoid): - Nitrates (e.g., nitroglycerin): can cause profound hypotension. - Guanylate cyclase stimulators (e.g., riociguat): risk of excessive blood pressure drop. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): increase vardenafil exposure. Moderate Interactions (Monitor Closely): - Alpha‑blockers (e.g., tamsulosin): may enhance blood‑pressure lowering effect. - Antihypertensives (e.g., beta‑blockers): monitor for additive hypotensive response. - CYP3A4 inducers (e.g., rifampin): may reduce therapeutic effectiveness.